Yi-Kuei Chen Acquires 20,000 Shares of Apollomics (NASDAQ:APLM) Stock

Apollomics Inc. (NASDAQ:APLM) COO Yi-Kuei Chen purchased 20,000 shares of the firm’s stock in a transaction dated Friday, August 14th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $300,000.00. Following the purchase, the chief operating officer directly owned 121,248 shares in the company, valued at approximately $1,818,720. This represents a 19.75% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Apollomics Stock Performance

APLM opened at $23.92 on Wednesday. Apollomics Inc. has a 1-year low of $3.66 and a 1-year high of $42.12. The stock’s 50 day simple moving average is $18.43 and its 200 day simple moving average is $17.34.

Institutional Trading of Apollomics

An institutional investor recently bought a new stake in Apollomics stock. Kestra Advisory Services LLC acquired a new position in shares of Apollomics Inc. (NASDAQ:APLM) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent reporting period. Hedge funds and other institutional investors own 19.13% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Apollomics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.